NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Louis Fries III
Dr. Glenn Gregory
Novavax, a clinical-stage vaccine company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, has made several promotions.
Amy Fix has been named senior VP, regulatory affairs. Ms. Fix joined Novavax in April 2013 as VP, regulatory affairs, and is responsible for regulatory strategy, regulatory operations, and interactions with international regulatory agencies, including the FDA, the European Medicines Agency, and a number of other global regulatory agencies.
Louis Fries III, M.D., has been named senior VP and chief medical officer. Dr. Fries joined Novavax in 2011 with more than 22 years of experience in clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments.
The company named Dr. Gregory Glenn president, research and development. Dr. Glenn joined Novavax as its chief scientific officer in July 2010.
Dr. Diego Miralles
Adaptive Biotechnologies Names President of Adaptive Therapeutics
Adaptive Biotechnologies, a leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, has appointed Diego Miralles, M.D., as president of Adaptive Therapeutics.
Most recently, Dr. Miralles was the global head, Johnson & Johnson Innovation, where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation.
Dr. Miralles is charged with building the therapeutics division of Adaptive and heading the company’s efforts to leverage its best-in-class platform for identifying T- and B-cell receptors for use in therapies that will directly impact patient outcomes.
Dr. Bruce Roberts
Vedanta Biosciences Appoints New Chief Scientific Officer
Vedanta Biosciences, which is pioneering the development of a new class of therapies designed to modulate the human microbiome, has appointed former Genzyme group VP, Bruce Roberts, Ph.D., as chief scientific officer.
Dr. Roberts has 30 years of experience in biotechnology and pharmaceutical drug discovery and development. He most recently served as head of neuroimmunology and immune-mediated disease research at Sanofi Genzyme where he directed preclinical efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into multiple clinical trials for the treatment of cancer, multiple sclerosis, and autoimmunity.
Bioclinica Expands eHealth Solutions’ Strategic Leadership Team
Bioclinica, a specialty clinical trials technology and services provider, has brought two industry experts on board to join its eHealth business segment leadership team.
Francois Audibert has been named VP for global consulting, responsible for data sciences, safety system, and process as well as the company’s life-sciences big data strategy. Mr. Audibert was most recently VP of pharmacovigilance at HighPoint Solutions.
Steven Herne is charged with heading Bioclinica eHealth Solutions global commercial endeavors across all three divisions comprising eClinical, safety and regulatory, and financial lifecycle solutions. Mr. Herne was most recently chief commercial officer at ERT where he was an executive member of the global leadership team, responsible for creating and executing the long-term strategic growth plan across all business lines.
Veristat Strengthens Senior Management Team
Veristat, a full-service CRO, has appointed Faith Haines Kolb to the newly created position VP of biometrics. She joins Veristat with more than 20 years of experience leading operational teams and large-scale projects during periods of rapid growth and international expansion for both large and small CROs. Most recently, she was the worldwide head of data management and bioostatistics for Parexel’s early phase group.
In her new role, she is responsible for leading the biostatistics and programming teams, as well as the data management and data standards groups at Veristat.
Cello Health Names Chief
Cello Health has appointed Jon Bircher as chief commercial officer, a new position aimed at building the brand positioning and proposition in the marketplace. He assumes responsibility for market positioning and reputation, as well as the commercialization of key cross-capability offerings. He joined Cello Health Consulting, formerly The MSI Consultancy, 10 years ago.
McCann Health Strengthens Leadership Team
McCann Health, the professional and consumer health and wellness global communications network, and part of McCann Worldgroup, has promoted Charlie Buckwell to president, Europe, Middle East & Africa (EMEA). Mr. Buckwell succeeds Michel Nakache, who is promoted to the newly created role of president, global clients unit. Mr. Buckwell continues to oversee McCann Complete Medical.
In addition, Simon Holt has been appointed to the newly created position of chief business strategy officer.
Mr. Holt, who joins the company from Novartis International, where he was global head public policy, also assumes leadership of McCann Health’s Double Helix Consulting & Double Helix Discovery units, succeeding Mr. Buckwell.(PV)